Silva J.G.,Escuela Militar de Graduados de Sanidad UDEFA |
Lopez J.,Escuela Superior de Medicina IPN |
Sanchez V.,Escuela Militar de Graduados de Sanidad UDEFA |
Sanchez V.,National Polytechnic Institute of Mexico |
And 2 more authors.
Journal of Nanoscience and Nanotechnology | Year: 2015
The use of magnetic nanoparticles have been proposed as alternative techniques to assist breast cancer diagnosis and treatment. Peritumoral and intratumoral biodistribution of magnetic nanoparticles have been the main practical approaches, and the evaluation of breast tumor tissue marked selectively by magnetic nanoparticles has been not widely studied so far. The aim of this study was to evaluate the c-erbB-2 antigen in tissue of a breast cancer animal model as specific target for the use of magnetic nanoparticles coupled to specific Monoclonal Antibody (Mab). A breast cancer animal model was adapted and standardized in female rats. Tumor tissue was characterized histopathological and inmunohistochemical for cancer type and c-erbB-2 expression respectively. A bioconjugate was developed by the covalent union of fluorescent magnetic nanoparticles and anti c-erbB-2 Mab, and was used for incubation in two consecutive slides of breast cancer tissue acoordingly following conditions: (a) the c-erbB-2 receptor previously blocked by a primary antibody, and (b) the c-erbB-2 receptor non-blocked. Microscopy fluorescence was used to determine the selective marked of tumor tissue by the bioconjugate. Healthy breast tissue was used as negative control of selective labeling of the bioconjugate. The results show a well-differentiated fluorescent mark by magnetic nanoparticles in the non-blocked c-erbB-2 receptor breast cancer tissue condition, the observation suggests the use of the c-erbB-2 antigen as specific target to mark selectively breast tumor tissue by magnetic nanoparticles. Copyright © 2015 American Scientific Publishers All rights reserved.
Silva-Escobedo J.G.,National Polytechnic Institute of Mexico |
Sanchez-Monroy V.,Escuela Militar de Graduados de Sanidad UDEFA |
Rojas-Lopez M.,National Polytechnic Institute of Mexico |
Lopez-Cruz J.,National Polytechnic Institute of Mexico |
Gonzalez C.A.,National Polytechnic Institute of Mexico
IEEE Transactions on Nanobioscience | Year: 2014
Breast cancer (BC) is the most frequent malignancy among women worldwide and has been associated with high mortality because of the late treatment of the disease. Our group has proposed a selective ablation of breast cancer cells by the use of magnetic fields assisted by magnetic nanoparticles. The principle is to increase the conductivity of tumoral tissue by the use of a bioconjugated 'nanoparticle-antibody' that recognizes specific antigens on the surface of the cancer cells. The aim of this study was to evaluate the c-erbB-2 antigen in breast cancer cells of type BT-474, MCF-7, and MDA-MB-231 as a possible target for the use of magnetic nanoparticles coupled to a specific Monoclonal Antibody (Mab). Quantitative real-time polymerase chain reaction and flow cytometry were used to estimate the relative expressions of the c-erbB-2 gene and the c-erbB-2 antigen in the cell lines, respectively. A covalent union of magnetic nanoparticles to anti c-erbB-2 Mab was used to develop the bioconjugate. Fluorescence microscopy was used to determine the cells that were tagged by the bioconjugate. The results show a well-differentiated relative expression of c-erbB-2 in the studied cell lines and are qualitatively in agreement with the fluorescent marking by the magnetic nanoparticles. The selected breast cancer cells appear to be suitable for experimental evaluation of selective targeting by magnetic nanoparticles. © 2002-2011 IEEE.